Search

This revised, expanded third edition updates the reader on this fast moving field as well providing an overall understanding of the genetics of complex diseases by using stroke as a paradigm. The reader will gain a comprehensive understanding of cerebrovascular genetics including the epidemiological evidence for the genetic basis of ischemic and hemorrhagic stroke, knowledge of its molecular basis from association, linkage and recent genome-wide studies, and also monogenic disorders. Finally, the legal and ethical complexities in dealing with these issues are discussed.Stroke Genetics is a valuable resource for neurologists, stroke physicians, hypertension specialists, internists, clinical pharmacologists and those in training, as well as researchers in the field of disease genetics. Each chapter now contains teaching/training MCQs to help with retention of information learnt from each chapter and this will be of considerable use to those training or about to the examined inthe field of inherited stroke.Additional questions via app: Download the Springer Nature Flashcards app for free and use exclusive additional material to test your knowledge.

This new edition of Pharmacoresistance in Epilepsy addresses all issues relating to drug-resistance in epilepsy, including studies in patients as well in experimental models and presents the basis for an understanding of recent developments in the pathogenesis and treatment of this condition. Important issues associated with drug-resistant epilepsy are reviewed and updated, such as abnormalities in inhibitory mechanisms, neurotoxicity and changes the immune system associated with this disorder, and the development of drug-resistance as consequence of chronic exposure to antiseizure-medications. Considering that a major obstacle is that epilepsy associated with drug-resistance cannot be controlled with the traditional antiseizure medications, specific chapters describe therapeutic strategies to prevent or reduce the progression of the disease with complementary medical therapies, such as transcranial focal stimulation to promote neuroprotection. Pharmacoresistance in Epilepsy is a valuable resource for anyone working in the field, whether studying epilepsy in the lab or treating it in an office.

This book provides a reference guide describing the current status of medication in all major psychiatric and neurological indications, together with comparisons of pharmacological treatment strategies in clinical settings in Europe, USA, Japan and China. In addition, it highlights herbal medicine as used in China and Japan, as well as complementary medicine and nutritional aspects. This novel approach offers international readers a global approach in a single dedicated publication and is also a valuable resource for anyone interested in comparing treatments for psychiatric disorders in three different cultural areas. There are three volumes devoted to Basic Principles and General Aspects, offering a general overview of psychopharmacotherapy (Vol. 1); Classes, Drugs and Special Aspects covering the role of psychotropic drugs in the field of psychiatry and neurology (Vol. 2) and Applied Psychopharmacotherapy focusing on applied psychopharmacotherapy (Vol. 3). These books are invaluable to psychiatrists, neurologists, neuroscientists, medical practitioners and clinical psychologists.

This book offers a detailed account of all aspects of photosensitive epilepsy, including genetic testing, functional imaging (fMRI, MEG), pharmacological studies, animal studies, classification based on the occurrence of photoparoxysmal responses (PPRs) in different epilepsy syndromes, and the available prevention and treatment options. In addition, the comorbidity of and overlap between migraine and epilepsy are discussed. Informative case histories with EEG examples and a helpful glossary are included. In epilepsy, the term photosensitivity is used both for epileptic seizures triggered by flashing or flickering light and for epileptiform discharges evoked by intermittent photic stimulation (IPS) during an EEG recording. Most patients with a clear history of visually induced seizures will show epileptiform EEG discharges during IPS (PPRs). As epileptiform discharges can be evoked in photosensitive patients at any time, without triggering seizures, theycan be considered a useful surrogate marker of the necessity and efficacy of epilepsy treatment. This book will serve as an ideal guide to the subject for pediatricians, (pediatric) neurologists, epileptologists, (child) psychiatrists, clinical geneticists, neuropsychologists, neuropharmacologists, occupational therapists, and basic scientists.

This ambitious and comprehensive handbook represents an essential contribution to our current understanding of interactions between heart and brain, a research topic generating growing interest. Despite the increasing awareness that neural mechanisms are the primary cause of cardiac disease and its progression, therapy continues to focus on end-organ protection and does not approach the neural core of the problem. Growing public health problems such as heart failure are still treated with autonomic drugs that are 30-40 years old and simply act on cardiac receptors. However, it has now been shown that the progression of ischemic heart disease to heart failure is mainly due to abnormal central responses to incipient cardiac disease, with neural activation the primary cause rather than the consequence of cardiac remodeling. Written by leading international experts in their respective research areas, the book presents a variety of perspectives on the coretopic: from social and philosophical to gender-related aspects.It is designed for a broad readership and includes dedicated sections for cardiologists, psychiatrists, neurologists and psychotherapists looking for a more insightful and targeted approach to neuro-cardiovascular disease.

This book offers valuable guidance to neurointensivists, other neurocritical care staff, and those desiring to develop a neurocritical care unit via a thorough discussion of neurological emergencies and neurocritical care unit organization.This comprehensive volume begins with a review of acute neurological emergencies as managed clinically in the neurocritical care unit. Topics include acute cerebrovascular, neurological, and neurosurgical disorders. The unique aspect of this book is its description of the organization of the neurocritical care unit. We focus on how other services in the hospital interact with and assist neurocritical care operations, telemedicine/telestroke, and neurocritical care personnel and their roles. A review of expected outcomes of neurocritical care conditions is also included.Neurointensivists, neurocritical care unit staff leadership, hospital administrators, and those interested in developing a neurocritical care unit will find Neurointensive Care Unit: Clinical Practice and Organization to be an invaluable guide.

This work is a guidebook for clinicians who are involved in treating depressive patients and also serves the research scientists who are working on the psychopharmacological mechanisms of antidepressant actions and psychopathological mechanisms underlying mood disorders. Mood disorders such as major depressive disorder (MDD), bipolar disorder (BPD) and seasonal affective disorder (SAD) are the most disabling disorders that are among the most expensive of all medical illnesses. The pathophysiology of mood disorders is very complex and involves many mechanisms like circadian rhythm disruption, sleep abnormalities, melatonin rhythm abnormalities and alterations in melatonin receptor mechanisms, abnormalities in monoaminergic neurotransmitter mechanisms, glutamatergic release mechanisms, hippocampal neurogenesis, and abnormal immune and cytokine release mechanisms. Many antidepressants that are in clinical use today including the recently introduced novel agentslike agomelatine or other antidepressants cause clinical remission by resynchronizing disrupted circadian rhythms and melatonin receptor functions, enhancing monoaminergic neurotransmission, promoting hippocampal neurogenesis, and regulating immune mechanisms. This book explains various etiological factors that are involved in the pathogenesis of mood disorders and the mechanisms of therapeutic actions of antidepressants including the recently introduced agomelatine and other antidepressants that exhibit rapid onset of action with greater efficacy and fewer side effects..

Dieser Buchtitel ist Teil des Digitalisierungsprojekts Springer Book Archives mit Publikationen, die seit den Anfängen des Verlags von 1842 erschienen sind. Der Verlag stellt mit diesem Archiv Quellen für die historische wie auch die disziplingeschichtliche Forschung zur Verfügung, die jeweils im historischen Kontext betrachtet werden müssen. Dieser Titel erschien in der Zeit vor 1945 und wird daher in seiner zeittypischen politisch-ideologischen Ausrichtung vom Verlag nicht beworben.

Band III der bekannten Reihe Neuropsychopharmaka stellt in der Neuauflage die aktuellsten medizinischen Präparate und klinischen sowie grundlagenorientierten Ergebnisse zum Thema Depressionssyndrom bzw. Antidepressiva vor. Der Band wurde in Anlehnung an die bereits erfolgten Neuauflagen der Bände IV und V neu gegliedert. Grundlegende Kapitel wurden vorangestellt, die eine Begründung für die im Buch dargestellten Therapiestrategien geben. Der Text wird durch Tabellen, Figuren und einen Medikamentenanhang anschaulich ergänzt. Die Neubearbeitung erfolgte durch eine große Anzahl von renommierten Psychiatern, Pharmakologen und Neurochemikern aus dem gesamten deutschsprachigen Raum, die für eine ausgewogene Darstellung sorgen. Das Buch liefert als einzigartiges Handbuch und Nachschlagewerk rasche Information zu allen Medikamenten. Die leserfreundliche Gliederung (detailliertes Inhaltsverzeichnis, ausführliches Stichwortverzeichnis, Tabellenwerk im Anhang) bietet die Möglichkeit, rasch eine Antwort zu erhalten.

The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi­ nimising the risks of an adverse event. Taking the idea further, pundits have pre­ dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as­ ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware­ ness of variation in drug metabolism and was correctly assigned to genetic poly­ morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera­ se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

Auch 25-30 Jahre nachdem Clozapin als erstes atypisches Antipsychotikum (atypisch = antipsychotisch wirksam ohne motorische Nebenwirkungen) auf den Markt gekommen ist, ist dieses Präparat in der Behandlung schizophrener Patienten weiterhin indiziert und sehr oft erfolgreich. Die 4-5 neuen atypischen Antipsychotika, die in den letzten 5 Jahren erfreulicherweise dazugekommen sind, haben Leponex nicht verdrängen können. Insbesondere in der Behandlung ansonsten weitgehend oder völlig therapieresistenter Patienten ist Clozapin unbestritten die Substanz, auf die sich die meisten behandelnden Ärzte verlassen. Das große klinische und wissenschaftliche Interesse an dieser einzigartigen Substanz wird deutlich durch die häufige Verabreichung und insbesondere auch durch die weiterhin zahlreichen präklinischen und klinischen Untersuchungen zum Wirkungsmechanismus, zur Wirkung und zur Verträglichkeit. Im vorliegenden Buch werden einige der aktuellen Studien vorgestellt.

This book is being published as we mark the end of the first 50 years of the modern antidepressant era. This era began with the chance discovery that tri- clic antidepressants and monoamine oxidase inhibitors had antidepressant p- perties. That discovery had three consequences. First, it brought simple and effective treatment to patients suffering from major depressive illnesses. Second, these discoveries, together with the discovery of lithium and chlorpromazine, began the remedicalization of psychiatry by making it clear that the treatment of many of the major psychiatric illnesses can be approached in the same way as other medical conditions. However, the most far-reaching effect was to provide the first clue as to what mechanisms might underlie antidepressant efficacy, a development that has led to an explosion in the number of available an- depressants and to their widespread use. The goal of this book is to provide a thorough review of the current status of antidepressants—how we arrived at this point in their evolution and where we are going in both the near and the long term. The book employs both a scientific and historical approach to accomplish these goals. The book is intended for practitioners who use antidepressants on a daily basis in their practice as well as for the student and researcher. Each will find that the book provides a comprehensive and logical approach to this important group of medications. The importance of the book is a function of its topic.